Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William Blair

Equities researchers at William Blair started coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The firm set an “outperform” rating on the stock.

A number of other research firms have also recently issued reports on GPCR. Stifel Nicolaus started coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, JMP Securities reissued a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Up 14.8 %

GPCR stock opened at $22.82 on Friday. The company has a market cap of $1.31 billion, a PE ratio of -30.84 and a beta of -2.75. Structure Therapeutics has a 52 week low of $19.61 and a 52 week high of $62.74. The business has a 50-day simple moving average of $26.66 and a 200 day simple moving average of $33.66.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new position in Structure Therapeutics during the 4th quarter worth approximately $34,000. Woodline Partners LP lifted its position in Structure Therapeutics by 0.7% in the 4th quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after acquiring an additional 2,328 shares in the last quarter. Vestal Point Capital LP boosted its stake in Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Twinbeech Capital LP increased its holdings in Structure Therapeutics by 34.3% during the 4th quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock worth $767,000 after purchasing an additional 7,220 shares in the last quarter. Finally, Tema Etfs LLC purchased a new stake in shares of Structure Therapeutics in the fourth quarter worth approximately $1,203,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.